Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Patient Trial Of Personalized Two-Drug Therapy For Brain Tumors Launched

06.04.2010
Avastin and Tarceva, which target different tumor-growth pathways, are being studied by the Brain Tumor Trials Collaborative, which includes 13 centers across the nation.

Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.

Cedars-Sinai’s Cochran Brain Tumor Center is the only site in California and one of only 13 in the nation offering this experimental therapy through the Brain Tumor Trials Collaborative (BTTC) based at M.D. Anderson Cancer Center in Houston.

Glioblastoma multiforme is a highly aggressive, treatment-resistant brain tumor. Even with standard therapies – surgery, chemotherapy and radiation – patient survival averages less than 15 months.

The two anticancer drugs, Avastin® (bevacizumab) and Tarceva® (erlotinib), work through different molecular mechanisms to attack brain tumors. Avastin inhibits vascular endothelial growth factor (VEGF), a protein that contributes to the formation of blood vessels that tumors need for growth. Tarceva is designed to prevent tumor growth by blocking a signal pathway that controls cell division by binding to a cancer cell membrane receptor called epidermal growth factor (EGFR).

Although single-agent targeted therapies have not produced significant improvements in treating glioblastomas, laboratory experiments and studies in animals suggest that a combination approach may have greater impact. This two-drug combination is also in clinical trials for the treatment of other cancers, including non-small cell lung cancer and renal cell carcinoma.

While all glioblastoma multiforme tumors share certain characteristics, they are not all genetically alike. This patient trial is specifically designed for those whose tumor cells have “unmethylated MGMT promoter.” This provides an especially strong study of the effects of the new two-drug approach because these tumors are resistant to the type of chemotherapy typically prescribed for patients with glioblastoma.

“Unmethylated MGMT promoter” means that a gene involved in repairing damaged tumor DNA is highly active in the tumor cells. When this gene, MGMT (O6-methylguanine-DNA methyltransferase), is functioning in cancer cells, it makes the tumor resistant to certain types of chemotherapy – including temozolamide, which is often used to treat glioblastoma – because it helps repair the damage the drug inflicts. On the other hand, if the gene is “silenced” (blocked) – through a process called methylation – the tumor will be more vulnerable to temozolomide.

The two-drug therapy will be administered after standard treatment with temozolomide and radiation therapy. Because radiation has been found to increase activation of certain molecular factors that the two drugs target, it is theorized that radiation therapy may stimulate a greater antitumor effect from the drugs.

Additional information on the clinical trial is available by calling 310-423-3062 or by visiting: http://www.cedars-sinai.edu/305.html.

The mission of the Brain Tumor Trials Collaborative “is to develop and perform hypothesis-based, state-of-the-art clinical trials in a collaborative and collegial environment, emphasizing innovation and meticulous attention to protocol compliance and date quality.” The group is led by researchers at M.D. Anderson Cancer Center in Houston and includes investigators at Cedars-Sinai and 11 other cancer research and treatment centers across the nation.

Other current members are: Baylor University Medical Center, Dallas; Dana Farber Cancer Center, Boston, M.D. Anderson Cancer Center – Orlando, Fla.; Medical University of South Carolina, Charleston; Memorial Sloan-Kettering Cancer Center, N.Y.; Methodist Hospital System, Houston; Northshore University Health System, Chicago; Northwestern University Feinberg School of Medicine, Chicago; Ohio State University A.G. James Cancer Hospital, Columbus; the University of Washington, Seattle; and the University of Texas Southwestern in Dallas.

Sandy Van | Cedars-Sinai News
Further information:
http://www.cedars-sinai.edu/305.html

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>